CHINA PHARMA HOLDINGS (CPHI) Company Report

China Pharma Holdings, Inc. held its annual stockholders' meeting on December 30, 2025, with 69.71% of outstanding shares present.
Stockholders elected Gene Michael Bennett, Yingwen Zhang, and Baowen Dong as independent directors.
A proposal to amend the Company's Articles of Incorporation to effect a reverse stock split at a ratio up to 1:20 was approved, though the Board of Directors retains discretion on its implementation.
The Amendment No.3 to the Company's Amended and Restated 2010 Long-Term Incentive Plan was also approved.

Jan 6, 2026, 9:05 PM

CHINA PHARMA HOLDINGS, INC. Subsidiary Acquires Ipragliflozin Patent

CPHI

New Projects/Investments

On December 22, 2025, China Pharma Holdings, Inc.'s subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement to acquire an invention patent for Ipragliflozin tablets.
The transfer price for the patent is $9.8 million, which will be paid by issuing 7,000,000 restricted shares of the Company's common stock at $1.40 per share.

Dec 23, 2025, 9:05 PM

China Pharma Holdings Subsidiary Acquires Patent for $6.3 Million

CPHI

New Projects/Investments

CHINA PHARMA HOLDINGS, INC.'s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement on December 4, 2025, to acquire an invention patent for a Captopril microcapsule and its preparation method from Lijie Tang.
The transfer price for the patent is $6.3 million.
The payment will be made in the form of 3,500,000 restricted shares of the Company's common stock, valued at $1.80 per share.

Dec 10, 2025, 9:49 PM

Stevanato Group Expands Drug Delivery Systems Capacity in Germany

CPHI

New Projects/Investments

Stevanato Group has significantly expanded its drug delivery system manufacturing capacity with a multi-million investment at its facility in Bad Oeynhausen, northern Germany.
The expansion includes over 2,500 square meters of advanced production space and an ISO 8 cleanroom environment for injection molding and automated assembly operations.
This initiative aims to strengthen global supply-chain integration, support proprietary devices such as the Aidaptus® autoinjector and Alina® pen injector platforms, and enhance operational flexibility and speed-to-market.
The expansion addresses the accelerating demand for drug delivery devices and rising patient adoption for more convenient, personalized treatment options.